Economic Observation Network Kolombotai has recently completed its H-share placement, and its stock price has fluctuated after the release of clinical data. Currently, it is still in the research and development stage and has not yet achieved stable profitability.

Financing situation:
Just before the release of clinical data, the company completed an H-share placement on July 10th, offering 5.838 million shares to institutional investors at a price of HKD 470.2 per share, raising a net capital of approximately HKD 2.723 billion, mainly for research and commercialization The placement price is discounted by 8.52% compared to the closing price of the day before the announcement.

Recent stock trends:
The stock price surged under the stimulation of positive news, reaching a high of HKD 560 on July 15th, but fell 2.61% to HKD 522.5 the next day (16th), indicating that some funds took profits after the positive news was realized. Goldman Sachs released a report after the data was released, raising its target price to HKD 582.95 and maintaining a 'buy' rating 。

Performance and business situation:
It should be noted that the company is still in the stage of "burning money" in research and development. The revenue growth rate in 2025 has significantly slowed down to 6.46%, and it continues to suffer losses. The operating cash flow is negative, and the operation is highly dependent on external financing This clinical success is a crucial step towards realizing commercial value, but there is still a way to go before generating stable income.

The above content is based on publicly available information and does not constitute investment advice.